phenoxodiol profile

phenoxodiol: a synthetic derivative of DAIDZEIN [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	219100
CHEMBL ID	1957038
SCHEMBL ID	149612
MeSH ID	M0445801

Synonym
unii-995ft1w541
995ft1w541 ,
idronoxil [usan:inn]
81267-65-4
D04498
idronoxil (usan/inn)
dehydroequol
nv 06
2h-1-benzopyran-7-ol, 3-(4-hydroxyphenyl)-
phenoxodiol
3-(4-hydroxyphenyl)-2h-1-benzopyran-7-ol
idronoxil
haginin e
ccris 8949
3-(4-hydroxyphenyl)-2h-chromen-7-ol
7-hydroxy-3-hydroxyphenyl-1h-benzopyran
haganin e
nv-06
isoflav-3-ene4',7-diol
ZZUBHVMHNVYXRR-UHFFFAOYSA-N
3-(4-hydroxy-phenyl)-2h-chromen-7-ol
isoflav-3-ene-4',7-diol
4',7-dihydroxyisoflav-3-ene
AKOS015918005
S9634
bdbm50419932
CHEMBL1957038
FT-0602222
NCGC00346822-01
nox-66 component idronoxil
idronoxil [usan]
dehydroequol [mi]
idronoxil component of nox66 suppository
idronoxil [inn]
(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2h-cromen-7-ol
idronoxil [who-dd]
nox66 suppository component idronoxil
DB04915
smr004701684
MLS006010720
SCHEMBL149612
DTXSID50231029
7,4'-dihydroxyisoflav-3-ene
phenoxodiol, >=98% (hplc)
Q27095562
HY-13721
idronoxil;dehydroequol;haginin e
CS-0007751
NCGC00346822-02
MS-23403
phenoxodiol (haginin e)
A853212
XD161580
...7,4?-dihydroxyisoflav-3-ene
XD161694

Research Excerpts

Overview

Phenoxodiol (PXD) is a synthetic analogue of the plant isoflavone genistein with improved anticancer efficacy. It is 5-20 times more potent than genisten and has broad in vitro activity against a number of human cancer cell lines.

Excerpt	Reference	Relevance
"Phenoxodiol is an isoflavene with potent anti-tumor activity. "	( Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity. Black, DS; Brandl, MB; Kumar, N; Vittorio, O; Yee, EMH, 2017)	1.9
"Phenoxodiol is an isoflavone analogue that possesses potent anticancer properties. "	( Preparation, characterization and in vitro biological evaluation of (1:2) phenoxodiol-β-cyclodextrin complex. Bhadbhade, MM; Black, DS; Brandl, MB; Hook, JM; Kuchel, RP; Kumar, N; Tilley, RD; Vittorio, O; Yee, EM, 2017)	2.13
"Phenoxodiol is an isoflavone analog with antitumor activity against a variety of cancers."	( Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway. Feng, J; Huang, X; Huang, Z; Li, Y, 2014)	2.57
"Phenoxodiol is an experimental anticancer drug under development as a chemosensitizer intended to reverse multidrug resistance mechanisms in ovarian and prostate cancer cells to most standard cytotoxics. "	( Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin. Kelly, G; McClain, N; Morré, DJ; Morré, DM; Wu, LY, 2009)	3.24
"Phenoxodiol is a novel isoflav-3-ene, currently undergoing clinical trials, that has a broad in vitro activity against a number of human cancer cell lines. "	( Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. de Souza, PL; Galettis, PT; McPherson, RA, 2009)	2.08
"Phenoxodiol (PXD) is a synthetic analogue of the plant isoflavone genistein with improved anticancer efficacy. "	( Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. Bamias, A; Constantinou, AI; Dimopoulos, MA; Georgaki, S; Husband, A; Ioannou, K; Nicolaou, KA; Skopeliti, M; Tsiatas, M; Tsitsilonis, OE, 2009)	3.24
"Phenoxodiol is a derivative of the isoflavone genisten that is 5-20 times more potent than genisten."	( Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Brown, DM; Husband, AJ; Lansigan, F; Saif, MW; Tytler, E, 2009)	1.45
"Phenoxodiol is a synthetic derivative of the naturally occurring plant isoflavone genistein. "	( Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Alvero, AB; Brown, D; Mor, G; Rutherford, TJ; Silasi, DA, 2009)	3.24
"Phenoxodiol is a novel isoflavone currently being studied in clinical trials for the treatment of cancer. "	( Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. de Souza, PL; Howes, JB; Howes, LG; Huang, LJ; West, L, 2011)	2.14
"Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo."	( Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE, 2011)	1.4
"Phenoxodiol is an isoflavone derivative that has been shown to elicit cytotoxic effects against a broad range of human cancers. "	( Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. Arfuso, F; Brown, D; Dharmarajan, A; Hisheh, S; Mahoney, S; Millward, M; Rogers, P, 2012)	2.08
"Phenoxodiol is a synthetic derivative of the plant isoflavone daidzein and is currently undergoing clinical testing as a cancer therapeutic drug."	( Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Constantinou, AI; Husband, A, )	2.3
"Phenoxodiol is a multi-pathway initiator of apoptosis with broad anti-tumor activity and high specificity for tumor cells. "	( Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Bukowski, RM; Choueiri, TK; Ganapathi, R; Hutson, TE; Kelly, GE; Mekhail, T, 2006)	2.12
"Phenoxodiol is a chemically modified analogue of the plant hormone isoflavone with antitumour activities. "	( Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells. Borrow, JM; Hersey, P; Watts, RN; Yu, F; Zhang, XD, 2006)	2.01
"Phenoxodiol is a new chemotherapeutic agent that has anti-proliferative and apoptotic effects on a range of cancer cells."	( Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model. Brown, D; Klein, R; Turnley, AM, 2007)	2.5

Effects

Excerpt	Reference	Relevance
"Phenoxodiol has a short plasma half-life, particularly in the free form, leading to a rapid attainment of steady state levels during continuous intravenous infusion."	( Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. de Souza, PL; Howes, JB; Howes, LG; Huang, LJ; West, L, 2011)	2.14
"Phenoxodiol has a short plasma half-life, particularly in the free form, leading to a rapid attainment of steady state levels during continuous intravenous infusion."	( Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. de Souza, PL; Howes, JB; Howes, LG; Huang, LJ; West, L, 2011)	2.14

Actions

Excerpt	Reference	Relevance
"Phenoxodiol did not inhibit topo I catalytic activity nor did it stabilize the topo I-mediated cleavable complex."	( Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Constantinou, AI; Husband, A, )	2.3

Treatment

Phenoxodiol treatment promoted a marked inhibition of proliferation and loss of colony formation in LNCaP cells. Treatment increased the number of annexin-V-positive cells as well as the expression of cleaved poly ADP ribose polymerase.

Excerpt	Reference	Relevance
"Phenoxodiol treatment promoted a marked inhibition of proliferation and loss of colony formation in LNCaP cells in a dose- and time-dependent manner. "	( Phenoxodiol inhibits growth of metastatic prostate cancer cells. Aguero, MF; Brown, DM; Espinoza, LA; Smulson, ME; Venero, M, 2010)	3.25
"Treatment with phenoxodiol increased the number of annexin-V-positive cells as well as the expression of cleaved poly ADP ribose polymerase, demonstrating that phenoxodiol induced apoptosis in renal cancer cells."	( Evaluation of Therapeutic Potential of Phenoxodiol, a Novel Isoflavone Analog, in Renal Cancer Cells. Asano, T; Isono, M; Okubo, K; Sato, A, 2018)	1.09
"Pre-treating Phenoxodiol sensitive cells with Phenoxodiol prior to Carboplatin resulted in XIAP degradation, associated with Carboplatin sensitization and apoptosis, whereas exposing Phenoxodiol resistant cells to Phenoxodiol resulted in less XIAP degradation and minimal Carboplatin sensitization."	( The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. Alvero, AB; Ariyan, S; Camp, RL; Kluger, HM; McCarthy, MM; Mor, G; Rimm, DL; Sznol, M, 2007)	0.9

Pharmacokinetics

Excerpt	Reference	Relevance
" Plasma sampling was undertaken to characterize the pharmacokinetic (PK) profile of the compound."	( Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. de Souza, PL; Howes, LG; Kelly, G; Liauw, W; Links, M; Pirabhahar, S, 2006)	0.59
" The plasma half-life (T1/2), clearance (Cl), and volume of distribution (VD) were 304 (+/-91) min, 82 (+/-19) ml/min and 32,663 (+/-7,199) ml, respectively, for total NV06."	( Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. de Souza, PL; Howes, LG; Kelly, G; Liauw, W; Links, M; Pirabhahar, S, 2006)	0.59

Compound-Compound Interactions

Excerpt	Reference	Relevance
" In this study, we determined the safety and efficacy of intravenous phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant ovarian cancers."	( Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE, 2011)	0.91

Bioavailability

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Whilst clinically tested in the past, idronoxil's journey was discontinued as a result of its low bioavailability in humans when administered either intravenously or orally, though strategies to overcome this issue are currently being explored."	( Idronoxil as an Anticancer Agent: Activity and Mechanisms. Delebecque, F; Fairlie, WD; Laczka, O; Porter, K; Wilkinson, J, 2020)	0.56

Dosage Studied

This phase I, single-center trial was conducted to test a continuous intravenous dosing regimen of phenoxodiol in patients with late-stage, solid tumors. Pharmacokinetics suggested a linear relationship between dosage and mean steady-state plasma concentrations.

Excerpt	Relevance	Reference
" This phase I, single-center trial was conducted to test a continuous intravenous dosing regimen of phenoxodiol in patients with late-stage, solid tumors to determine toxicity, pharmacokinetics, and preliminary efficacy."	( Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Bukowski, RM; Choueiri, TK; Ganapathi, R; Hutson, TE; Kelly, GE; Mekhail, T, 2006)	0.89
" Pharmacokinetics suggested a linear relationship between dosage and mean steady-state plasma concentrations of phenoxodiol."	( Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Bukowski, RM; Choueiri, TK; Ganapathi, R; Hutson, TE; Kelly, GE; Mekhail, T, 2006)	0.88
"Responses were evaluated from dose-response curves of the metabolites and metabolic inhibitors in which growth of HeLa cells, apoptosis based on DAPI fluorescence and cytosolic NADH levels were correlated with sphingomyelinase and spingosine kinase activities and levels of ceramide and sphingosine1-phosphate."	( Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol. De Luca, T; Morré, DJ; Morré, DM; Watanabe, T; Wu, LY, 2011)	0.6

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	10.4904	0.0030	8.7949	48.0869	AID1347053
PPM1D protein	Homo sapiens (human)	Potency	11.7086	0.0052	9.4661	32.9993	AID1347411
EWS/FLI fusion protein	Homo sapiens (human)	Potency	4.7188	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
polyprotein	Zika virus	Potency	10.4904	0.0030	8.7949	48.0869	AID1347053
Interferon beta	Homo sapiens (human)	Potency	11.7086	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Estrogen receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.6607	0.0007	4.1521	14.1600	AID650636
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay ID	Title	Year	Journal	Article
AID737840	Antiproliferative activity against human SHEP cells by measuring metabolic activity of cells after 72 hrs by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID1474778	Growth inhibition of human SK-N-BE(2) cells after 72 hrs by Alamar blue assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
AID650641	Vasorelaxant activity in Sprague-Dawley rat thoracic aorta assessed as inhibition of phenylephirne-induced contraction	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition.
AID1474777	Selectivity ratio of IC50 for human MRC5 cells to GI50 for human MDA-MB-231 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
AID650636	Displacement of [3H]estradiol from rat uterine cytosolic estrogen receptor	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition.
AID1162585	Antiproliferative activity against human SHEP cells after 72 hrs by Alamar blue/spectrophotometric analysis	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Synthesis, anti-cancer and anti-inflammatory activity of novel 2-substituted isoflavenes.
AID1474782	Selectivity ratio of IC50 for human MRC5 cells to GI50 for human U87 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
AID1474781	Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
AID737833	Antiangiogenic activity in human HMEC1 cells at 5 uM after 8 hrs by matrigel assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID737841	Antiproliferative activity against human MDA-MB-231 cells by measuring metabolic activity of cells after 72 hrs by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID1474776	Selectivity ratio of IC50 for human MRC5 cells to GI50 for human SK-N-BE(2) cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
AID1162586	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by Alamar blue/spectrophotometric analysis	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Synthesis, anti-cancer and anti-inflammatory activity of novel 2-substituted isoflavenes.
AID737834	Antiangiogenic activity in human HMEC1 cells at 1 uM after 8 hrs by matrigel assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID1474780	Growth inhibition of human U87 cells after 72 hrs by Alamar blue assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
AID737836	Selectivity ratio of GI50 for human MRC5 cells to GI50 for human MDA-MB-231 cells	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID1474779	Growth inhibition of human MDA-MB-231 cells after 72 hrs by Alamar blue assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
AID737837	Selectivity ratio of GI50 for human MRC5 cells to GI50 for human SHEP cells	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID737842	Antiproliferative activity against human HMEC1 cells by measuring metabolic activity of cells after 72 hrs by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID737835	Antiangiogenic activity in human HMEC1 cells at 10 uM after 8 hrs by matrigel assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID650640	Vasorelaxant activity in Sprague-Dawley rat thoracic aorta assessed as inhibition of phenylephirne-induced contraction in presence of 0.1 uM estrogen receptor antagonist ICI 182780	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition.
AID737839	Antiproliferative activity against human MRC5 cells by measuring metabolic activity of cells after 72 hrs by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID650639	Vasorelaxant activity in Sprague-Dawley rat thoracic aorta assessed as inhibition of U46619-induced vascular tension at 100 uM pretreated for 30 mins	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition.
AID650637	Vasorelaxant activity in Sprague-Dawley rat thoracic aorta assessed as inhibition of U46619-induced GTP RhoA level at 100 uM pretreated for 30 mins measured after 45 mins by spectrometric analysis	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition.
AID737838	Selectivity ratio of GI50 for human MRC5 cells to GI50 for human HMEC1 cells	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (53.13)	29.6817
2010's	21 (32.81)	24.3611
2020's	9 (14.06)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (8.96%)	5.53%
Reviews	9 (13.43%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	52 (77.61%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
embelin embelin: from Embelia fruit (Myrsinaceae). embelin : A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease.	2.17	1	0	dihydroxy-1,4-benzoquinones	antimicrobial agent; antineoplastic agent; hepatitis C protease inhibitor; plant metabolite
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.08	1	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
9,10-dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.	2.01	1	0	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
morpholine [no description available]	2.07	1	0	morpholines; saturated organic heteromonocyclic parent	NMR chemical shift reference compound
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.96	4	0	catechin	antioxidant; plant metabolite
thiazoles [no description available]	2.05	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
flavone flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.	2.07	1	0	flavones	metabolite; nematicide
deoxycytidine [no description available]	2.46	2	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	5.26	4	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	7.03	1	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	7.46	2	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.41	1	0	D-glucopyranose	epitope; mouse metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.05	1	0	organic bromide salt	colorimetric reagent; dye
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.96	4	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
equol Equol: A non-steroidal ESTROGEN generated when soybean products are metabolized by certain bacteria in the intestines.	7.77	3	0	hydroxyisoflavans
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.07	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
omega-n-methylarginine omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.	3.4	1	1	amino acid zwitterion; arginine derivative; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.02	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
dihydrodaidzein dihydrodaidzein: structure in first source. dihydrodaidzein : A hydroxyisoflavanone that is isoflavanone carrying two hydroxy substituents located at positions 4' and 7.	2.72	3	0	hydroxyisoflavanone	metabolite
carboplatin [no description available]	5.04	3	1
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.15	1	0	cyclodextrin
glycosides [no description available]	7.82	2	0
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.02	1	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
nadp [no description available]	2.06	1	0
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	4.9	6	0	sphing-4-enine	human metabolite; mouse metabolite
genistein [no description available]	2.15	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
coenzyme q10 coenzyme Q10: Ubiquinone ring with a chain of 10 isoprene units; redox equilibrium with ubiqunol serving in mitochondrial inner membrane to transfer electrons; presence during reconstitution of acetylcholine receptor into phospholipid vesicles yields vesicles active in catalyzing carbamylcholine-sensitive Na+ flux; coenzyme Q10 depletion has been noted with use of statins. coenzyme Q10 : A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration.	2.03	1	0	ubiquinones	antioxidant; ferroptosis inhibitor; human metabolite
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	4.9	6	0	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)	2.07	1	0
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	2.73	3	0	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
sphingosine kinase [no description available]	7.96	4	0
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	2.43	2	0
phytoestrogens Phytoestrogens: Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS.	2.47	2	0
okadaic acid Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.	2.04	1	0	ketal
tetrahydrodaidzein tetrahydrodaidzein: structure in first source	2.72	3	0

Condition	Indicated	Relationship Strength	Studies	Trials
Breast Cancer [description not available]	0	3.86	2	1
Breast Neoplasms Tumors or cancer of the human BREAST.	0	3.86	2	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	2.08	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Coronary Restenosis Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.	0	2.03	1	0
Benign Neoplasms [description not available]	0	8	10	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	10	10	2
Cancer of Ovary [description not available]	0	7.9	9	2
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1	9.9	9	2
Adenocarcinoma, Clear Cell An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)	0	2.17	1	0
Adenocarcinoma Of Kidney [description not available]	0	2.17	1	0
Cancer of Kidney [description not available]	0	2.17	1	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	0	2.17	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	2.17	1	0
Neoplasms, Cystic, Mucinous, and Serous Neoplasms containing cyst-like formations or producing mucin or serum.	0	4.4	1	1
Cancer of Gallbladder [description not available]	0	2.1	1	0
Gallbladder Neoplasms Tumors or cancer of the gallbladder.	0	2.1	1	0
Adenocarcinoma, Basal Cell [description not available]	0	2.1	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	2.1	1	0
Angiogenesis, Pathologic [description not available]	0	3.35	2	0
Cancer of Prostate [description not available]	0	5.6	6	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	5.6	6	1
Biliary Tract Cancer [description not available]	0	2.96	1	0
Cancer of Pancreas [description not available]	0	2.96	1	0
Biliary Tract Neoplasms Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.	0	2.96	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	2.96	1	0
Acute Lymphoid Leukemia [description not available]	0	2.05	1	0
Acute Myelogenous Leukemia [description not available]	0	2.05	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.05	1	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	0	2.05	1	0
Hormone-Dependent Neoplasms [description not available]	0	2.05	1	0
Epithelial Ovarian Cancer [description not available]	0	4.37	1	1
Epithelial Neoplasms [description not available]	0	4.37	1	1
Peritoneal Carcinomatosis [description not available]	0	4.37	1	1
Cancer of the Fallopian Tube [description not available]	0	4.37	1	1
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	0	4.37	1	1
Fallopian Tube Neoplasms Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.	1	6.37	1	1
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	1	6.37	1	1
Osteogenic Sarcoma [description not available]	0	2.07	1	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	7.07	1	0
Animal Mammary Carcinoma [description not available]	0	2.01	1	0
Carcinoma, Anaplastic [description not available]	0	2.43	2	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	0	2.43	2	0
Carcinoma, Epidermoid [description not available]	0	2.02	1	0
Cancer of Head [description not available]	0	2.02	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.02	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	2.02	1	0
Bone Cancer [description not available]	0	2.02	1	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	2.02	1	0
Innate Inflammatory Response [description not available]	0	2.03	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.03	1	0
Lymphocytopenia [description not available]	0	3.41	1	1
Lymphopenia Reduction in the number of lymphocytes.	0	3.41	1	1
Malignant Melanoma [description not available]	0	2.44	2	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	2.44	2	0
Metastase [description not available]	0	2.03	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	2.03	1	0
Peripheral Nerve Diseases [description not available]	0	2.03	1	0
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	0	2.03	1	0

phenoxodiol

Description

Cross-References

Synonyms (55)

Research Excerpts

Overview

Effects

Actions

Treatment

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (6)

Potency Measurements

Inhibition Measurements

Biological Processes (30)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (54)

Research

Studies (64)

Market Indicators

Research Demand Index: 21.80

Study Types

phenoxodiol

Description

Cross-References

Synonyms (55)

Research Excerpts

Overview

Effects

Actions

Treatment

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (6)

Potency Measurements

Inhibition Measurements

Biological Processes (30)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (54)

Research

Studies (64)

Market Indicators

Research Demand Index: 21.80

Study Types

Related Drugs (35)

Related Conditions (61)